Testing a treatment break in multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial is for people with multiple myeloma who have already completed 12 cycles of a standard treatment (daratumumab, lenalidomide, and dexamethasone) and are doing well. It tests whether taking a break from treatment is safe and effective, instead of continuing without a break.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma and have finished 12 cycles of treatment with daratumumab, lenalidomide, and dexamethasone.
- Your disease is at least partially controlled (partial response or better) after those 12 cycles.
- Your blood counts are adequate (ANC at least 1.0 and platelets at least 75).
- You have not stopped taking daratumumab or lenalidomide for any reason (only dexamethasone can be stopped or reduced).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This trial tests a combination of two drugs, daratumumab and lenalidomide, for patients with multiple myeloma that has not responded to previous treatments. It aims to see if this regimen can help when other therapies have stopped working.
This trial compares stopping treatment after a set number of cycles versus continuing it for people over 65 or those who cannot have a stem cell transplant. It tests whether a fixed treatment period works as well as long-term treatment for newly diagnosed multiple myeloma.
This trial tests a personalized approach to maintenance therapy for people with multiple myeloma who have already had a stem cell transplant. Your treatment plan may be adjusted based on how well your cancer responds and on certain risk factors, with the goal of keeping you in remission longer.
This trial tests two medicines, iberdomide and daratumumab, given as maintenance therapy after an autologous stem cell transplant. It is for people with multiple myeloma who still have small amounts of cancer cells detected after transplant and who have already been treated with a daratumumab-containing regimen.
This trial tests different dosing schedules of daratumumab to find a more cost-effective option for patients with multiple myeloma who have already had a stem cell transplant and achieved at least a partial response. It aims to see if a lower dose can work just as well.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.